Use of Oxygen in Heart Failure With Preserved Ejection Fraction

NCT ID: NCT02949531

Last Updated: 2019-06-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-03

Study Completion Date

2017-02-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Oxygen is routinely given to patients with common conditions such as COPD and heart failure. There is no evidence behind giving oxygen to patients specifically in heart failure due to a stiff heart.

This study aims to explore the effect oxygen has on the ability of patients with chronic heart failure and the ability to exercise. Other common variables will be assessed such as heart rate and blood pressure to observe the response to varying concentrations of oxygen.

The concentrations chosen are commonly offered in hospitals and indeed are being delivered through standard equipment found in all hospitals in the country.

It is hoped that studying the effect of short term oxygen on patients with heart failure will help to identify the effectiveness of oxygen in longer term therapy for patients who are often breathless with a decreased exercise tolerance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Many patients with reduced exercise tolerance have a preserved left ventricular function. These patients are labelled as having heart failure with preserved ejection fraction (HeFPEF), when the combined use of echocardiography and biochemistry. The prevalence and the incidence of HeFPEF are on the increase and currently it accounts for around 50% of all patients diagnosed with HF. The last twenty years of research has led to great improvement in available treatments for heart failure with reduced ejection fraction (HeFREF); however, current guidelines only suggest diuretics to improve symptoms of those patients with HeFPEF: clinical trials of several pharmacological interventions have failed to show convincing reductions in morbidity or mortality for patients with HeFPEF.

The effect of oxygen therapy on exercise capacity has remained poorly understood in HeFREF and, at the time of writing this study, it has never been explored in HeFPEF. The investigators recently completed a study showing an increase in exercise time, exercise load at peak exercise and peak metabolic equivalent on cycle ergometry with 28% oxygen supplementation and further increments when 40% oxygen supplementation was used in patients with heart failure with reduced ejection fraction.

The investigators aim to improve exercise time in patients with HeFPEF with oxygen supplementation. Identifying the correct dose of oxygen will be a further aim to avoid hyperoxygenation but provide adequate oxygen to improve exercise tolerance.

Patients will be identified from heart failure clinics and will be invited for screening visit. Eligible patients will have three treatment visit at least one week apart (each visit with a different oxygen concentration i.e room air, 28% and 40% oxygen, randomly determined by sealed envelopes)

Patients will use standard cycle ergometry to exercise and work load will be increased every minute by 5-10 watts. Patients will be encouraged to cycle until tired. At the end of cycling, exercise time, peak metabolic equivalent, work load, shortness of breath score will be noted at each visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

21% oxygen

room air will be delivered via Venturi mask during cycle ergometry

Group Type ACTIVE_COMPARATOR

oxygen

Intervention Type DRUG

28% oxygen

28% oxygen will be delivered via Venturi mask during cycle ergometry

Group Type ACTIVE_COMPARATOR

oxygen

Intervention Type DRUG

40% oxygen

40% oxygen will be delivered via Venturi mask during cycle ergometry

Group Type ACTIVE_COMPARATOR

oxygen

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

oxygen

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Over 50 years of age and able and willing to give consent
* Have signs and/or symptoms of heart failure
* Left ventricular ejection fraction \> 45%
* NT-pro BNP \> 220 pg/ml (in the previous 12 months)
* On any diuretic

Exclusion Criteria

* Unable or unwilling to give consent
* Recent (\<1 month) acute myocardial infarct or cerebrovascular event
* Significant renal dysfunction (eGFR \<30 ml.min-1.1.73m-2)
* Significant anaemia (Haemoglobin \< 100 g.L-1)
* Systolic blood pressure \<90 mmHg, or \>180 mmHg
* Severe mitral or aortic valve disease
* Diagnosis of severe chronic lung disease
* Involvement in another medicinal trial within the past four weeks
* Unable to use cycle
* Any planned admission in the following 3-4 weeks (patient can be reconsidered for enrolment after planned admission)
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hull University Teaching Hospitals NHS Trust

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andrew Clark

Role: PRINCIPAL_INVESTIGATOR

Castle Hill Hospital

References

Explore related publications, articles, or registry entries linked to this study.

Shah P, Pellicori P, Rimmer S, Rigby AS, Clark AL. Effect of increased inspired oxygen on exercise performance in patients with heart failure and normal ejection fraction. Int J Cardiol. 2018 Oct 1;268:166-169. doi: 10.1016/j.ijcard.2018.05.029. Epub 2018 May 24.

Reference Type BACKGROUND
PMID: 29803343 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

R1965

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Provocative Tests for HFpEF
NCT06309550 RECRUITING
Interval Training in Heart Failure
NCT03955029 RECRUITING NA
Nasal High Flow at Acute Hart Failure
NCT02058810 TERMINATED NA
The Use of Advanced Imaging in HFpEF
NCT06905405 NOT_YET_RECRUITING